Prevention of hepatotoxicity due to anti tuberculosis treatment: A novel integrative approach

World Journal of Gastroenterology

Volumn 14, Issue 30, 2008, Pages 4753-4762

  Adhvaryu, Meghna R ^a   Reddy, Narsimha M ^a   Vakharia, Bhasker C ^b  

^a VEER NARMAD SOUTH GUJARAT UNIVERSITY   (India)

^b Shree Gurudev Sarvajanik Charitable Trust Mobile Clinic   (India)

Author keywords

Anti tuberculous treatment; Curcumin longa; Hepatoprotection; Tinospora cordifolia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CURCUMA LONGA EXTRACT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TINOSPORA CORDIFOLIA EXTRACT; HEMOGLOBIN; PLANT MEDICINAL PRODUCT; TUBERCULOSTATIC AGENT;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; TREATMENT DURATION; TUBERCULOSIS; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; CURCUMA LONGA; DRUG COMBINATION; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; LIVER DISEASE; METABOLISM; MIDDLE AGED; PATIENT COMPLIANCE; TINOSPORA; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; BLOOD SEDIMENTATION; BODY WEIGHT; CURCUMA; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HEMOGLOBINS; HUMANS; ISONIAZID; LIVER DISEASES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLANT PREPARATIONS; PYRAZINAMIDE; RIFAMPIN; TINOSPORA; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 55449120791     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.4753     Document Type: Article

References (50)

1. Runyon EH. Preventive Treatment in Tuberculosis: A Statement by the Committee on Therapy. American Thoracic Society. Am Rev Respir Dis 1965; 91: 297-298
2. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972; 106: 357-365
3. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001
4. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471
5. Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ 2002; 325: 1282-1286
6. Mahashur AA, Prabhudesai PP. Hepatitis and antitubercular therapy. J Assoc Physicians India 1991; 39: 595-596
7. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50: 289-291
8. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50: 733-735
9. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002; 51: 998-999
10. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26: 462-464
11. Raviglione MC, Snider DE Jr , Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226
12. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2002. Communicable Diseases 2002: 237
13. Fernandez-Villar A, Sopena B, Fernandez-Villar J, Vazquez-Gallardo R, Ulloa F, Leiro V, Mosteiro M, Pineiro L. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004; 8: 1499-1505
14. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002; 6: 699-705
15. Wada M. [The adverse reactions of anti-tuberculosis drugs and its management] Nippon Rinsho 1998; 56: 3091-3095
16. Attri S, Rana SV, Vaiphei K, Sodhi CP, Katyal R, Goel RC, Nain CK, Singh K. Isoniazid- and rifampicin-induced oxidative hepatic injury - protection by N-acetylcysteine. Hum Exp Toxicol 2000; 19: 517-522
17. Richards VE, Chau B, White MR, McQueen CA. Hepatic gene expression and lipid homeostasis in C57BL/6 mice exposed to hydrazine or acetylhydrazine. Toxicol Sci 2004; 82: 318-332
18. Karthikeyan S. Isoniazid and rifampicin treatment on phospholipids and their subfractions in liver tissue of rabbits. Drug Chem Toxicol 2005; 28: 273-280
19. Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 2006; 45: 117-126
20. Yue J, Peng RX, Yang J, Kong R, Liu J. CYP2E1 mediated isoniazid induced hepatotoxicity in rats. Acta Pharmacol Sin 2004; 5: 699-704
21. Tasduq SA, Kaisar P, Gupta DK, Kapahi BK, Maheshwari HS, Jyotsna S, Johri RK. Protective effect of a 50% hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity. Phytother Res 2005; 19: 193-197
22. Adhvaryu MR, Reddy N, Parabia MH. Effects of four Indian medicinal herbs on Isoniazid-, Rifampicin- and Pyrazinamide-induced hepatic injury and immunosuppression in guinea pigs. World J Gastroenterol 2007; 13: 3199-3205
23. National Toxicology Program. NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1) (Major Component 79%-85% Curcumin, CAS No. 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 1993 427: 1-275
24. Kapil A, Sharma S. Immunopotentiating compounds from Tinospora cordifolia. J Ethnopharmacol 1997; 58: 89-95
25. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895-900
26. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7: 1894-1900
27. Adverse Reactions. In: Evaluation of a new class I substance- Tinospora cordifolia (Guduchi). IJEACCM New Zealand 2006: 43
28. Pade SD. [Translated book from Marathi to Gujarati] Aryabhishak, 17th ed. Sastu Sahitya Vardhak Karyalaya, Mumbai, 1983: 440-441
29. Pade SD. [Translated book from Marathi to Gujarati] Aryabhishak, 17th ed. Sastu Sahitya Vardhak Karyalaya, Mumbai, 1983: 202-205
30. Matsuo T, Toyota A, Kanamori H, Nakamura K, Katsuki S, Sekita S, Satake M. Constituents of Representative Curcuma And Estimation of Curcuma species in Health Foods. Bulletin of the Hiroshima Prefectural Institute of Public Health and Environment. 2002; 10: 7-13
31. Leela NK, Tava A, Shafi PM, John SP, Chempakam B. Chemical composition of essential oils of turmeric (Curcuma longa L) Acta Pharm 2002; 52: 137-141
32. Singh SS, Pandey SC, Srivastava S, Gupta VS, Patro B, Ghosh AC. Chemistry and medicinal properties of Tinospora cordifolia (Guduchi). Indian J Phamacol 2003; 35: 83-91
33. Rej R. Aminotransferases in disease. Clin Lab Med 1989; 9: 667-687
34. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655
35. Ahmed SK. A word of advice for those with sickle cell anaemia. 2008
36. State govt constitutes group to study sickle cell disease. 1998
37. Song EK, Cho H, Kim JS, Kim NY, An NH, Kim JA, Lee SH, Kim YC. Diarylheptanoids with free radical scavenging and hepatoprotective activity in vitro from Curcuma longa. Planta Med 2001; 67: 876-877
38. Lukita-Atmadja W, Ito Y, Baker GL, McCuskey RS. Effect of curcuminoids as anti-inflammatory agents on the hepatic microvascular response to endotoxin. Shock 2002; 17: 399-403
39. Reddy AC, Lokesh BR. Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes. Mol Cell Biochem 1992; 111: 117-124
40. Singh RP, Banerjee S, Kumar PV, Raveesha KA, Rao AR. Tinospora cordifolia induces enzymes of carcinogen/drug metabolism and antioxidant system, and inhibits lipid peroxidation in mice. Phytomedicine 2006; 13: 74-84
41. Desai VR, Kamat J P, Sainis K B. An immuno-modulator from Tinospora cordifolia with antioxidant activity in cell free systems. Proc Indian Acad Sci (chem. Sci) 2002; 114: 713-719
42. Wagner H. Multitarget therapy - the future of treatment for more than just functional dyspepsia. Phytomedicine 2006; 13 Suppl 5: 122-129
43. Beller EM, Gebski V, Keech AC. Randomisation in clinical trials. Med J Aust 2002; 177: 565-567
44. Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 2007; 43: 859-866
45. Cohen-Solal M, Prehu C, Wajcman H, Poyart C, Bardakdjian-Michau J, Kister J, Prome D, Valentin C, Bachir D, Galacteros F. A new sickle cell disease phenotype associating Hb S trait, severe pyruvate kinase deficiency (PK Conakry), and an alpha2 globin gene variant (Hb Conakry). Br J Haematol 1998; 103: 950-956
46. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9: 2026-2030
47. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996; 22: 211-214
48. Laftah AH, Sharma N, Brookes MJ, McKie AT, Simpson RJ, Iqbal TH, Tselepis C. Tumour necrosis factor alpha causes hypoferraemia and reduced intestinal iron absorption in mice. Biochem J 2006; 397: 61-67
49. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006; 69: 195-206
50. Fairbanks K. Alcoholic liver disease. Gastroenterology & Hepatology 2004